Hikma Pharmaceuticals PLC (HIK)

2,365.00
-10.00(-0.42%)
  • Volume:
    284,445
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    2,365.00 - 2,410.00

HIK Overview

Prev. Close
2,375
Day's Range
2,365-2,410
Revenue
2.58B
Open
2,384
52 wk Range
2,158-2,768
EPS
1.47
Volume
284,445
Market Cap
5.47B
Dividend (Yield)
37.75
(1.59%)
Average Volume (3m)
292,849
P/E Ratio
16.14
Beta
0.22
1-Year Change
-6.52%
Shares Outstanding
231,440,797
Next Earnings Date
23 Feb 2022
What is your sentiment on Hikma Pharmaceuticals PLC?
or
Market is currently closed. Voting is open during market hours.

Hikma Pharmaceuticals PLC News

Hikma Pharmaceuticals PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

Hikma Pharmaceuticals PLC Company Profile

Hikma Pharmaceuticals PLC Company Profile

Employees
8681

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Read More
  • Touch 27 today
    0
    • Next results will be super. Wait for it to hit £32 before end of this year
      0
      • Aim listed Dark Matter Ltd, has more potential
        1
        • This will go up & up
          1
          • Not as stated here (March 11)
            1
            • Hikma will announce their results for the year ended 31 December 2019 on 27 February 2020
              0
              • Any hint of progress on Advair will send this stock much higher still !
                0
                • Underpriced without the Advair approvals ' unfortunate about the 2019 target for Advair !!!
                  0
                  • Almost got me money back !!!
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.